Sinclair v. Teva Pharmaceuticals, USA, Inc. ( 2023 )

TAL I 6/29/2023 FILED UNITED STATES JUDICIAL PANEL P. WEIMER, Clerk on Jul 06, 2023 MULTIDISTRICT LITIGATION EASTERN DISTRICT OF CALIFORNIA s/J. Arnold Deputy Clerk IN RE: PARAGARD IUD PRODUCTS LIABILITY LITIGATION MDL No. 2974 (SEE ATTACHED SCHEDULE) CONDITIONAL TRANSFER ORDER (CTO —57) On December 16, 2020, the Panel transferred 49 civil action(s) to the United States District Court for the Northern District of Georgia for coordinated or consolidated pretrial proceedings pursuant to 28 U.S.C. § 1407. See 510 F.Supp.3d 1376 (J.P.M.L. 2020). Since that time, 239 additional action(s) have been transferred to the Northern District of Georgia. With the consent of that court, all such actions have been assigned to the Honorable Leigh Martin May. It appears that the action(s) on this conditional transfer order involve questions of fact that are common to the actions previously transferred to the Northern District of Georgia and assigned to Judge May. Pursuant to Rule 7.1 of the Rules of Procedure of the United States Judicial Panel on Multidistrict Litigation, the action(s) on the attached schedule are transferred under 28 U.S.C. § 1407 to the Northern District of Georgia for the reasons stated in the order of December 16, 2020, and, with the consent of that court, assigned to the Honorable Leigh Martin May. This order does not become effective until it is filed in the Office of the Clerk of the United States District Court for the Northern District of Georgia. The transmittal of this order to said Clerk shall be stayed 7 days from the entry thereof. If any party files a notice of opposition with the Clerk of the Panel within this 7-day period, the stay will be continued until further order of the Panel. Inasmuch as no objection is FOR THE PANEL: Says ited aye Db Jun 29, 2023 CLERK'S OFFICE . ens Tiffaney D. Pete Clerk of the Panel INRE:PARAGARDIUDPRODUCTSLIABILITY LITIGATION MDLNo.2974 SCHEDULECTO−57−TAG−ALONGACTIONS DIST DIV. C.A.NO. CASECAPTION CALIFORNIAEASTERN CAE 2 23−01134 Sinclairv.TevaPharmaceuticals,USA,Inc.etal